Sotera Pops on Q2 Figures
Sotera Health Company (NASDAQ: SHC) shares began Friday sharply higher. The Cleveland-based company, a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three months ended June 30, 2025.
Second-quarter 2025 net revenues increased 6.4% to $294 million, compared to $277 million in the second-quarter 2024. Net revenues increased 6.0% on a constant currency basis. Net income was $8 million, or $0.03 per diluted share, which includes a pending and previously disclosed settlement of approximately $34 million related to ethylene oxide claims against Sterigenics, compared to net income of $9 million, or $0.03 per diluted share, in the second-quarter of 2024.
Adjusted EBITDA for the second-quarter 2025 increased 9.8% to $151 million compared to the second-quarter 2024, or 9.5% on a constant currency basis. Second-quarter 2025 Adjusted Earnings Per Diluted Share increased $0.01 to $0.20 compared to the second quarter of 2024.
Said CEO Michael Petras, “We are pleased to announce that we delivered more than 6% top-line growth for the quarter, supported by strong volume performance at Sterigenics. Adjusted EBITDA grew nearly 10% in the quarter with approximately 160 basis points of margin expansion, driven by over 500 basis points of improvement at Nelson Labs. These positive results reflect the essential nature of our services and our team’s disciplined execution.”
SHC shares leaped $2.20, or 19.7%, to $13.43.
